文献速递淋巴瘤

慢性淋巴细胞白血病的克隆动力学

Clonal dynamics in chronic lymphocytic leukemia.
PubMed 文献 · Blood Adv · 2019-01-01

慢性淋巴细胞白血病病程高度可变,被认为由大规模DNA测序研究揭示的患者间及患者内分子异质性驱动。近五年靶向药物获批但多数患者仍复发,全基因组测序有助于识别亚克隆群体及其突变谱、治疗反应和生长动力学,理解遗传、表观遗传和转录组特征对克隆生长和药物反应的影响是选择和治疗时机的重要步骤。

要点

  • 慢性淋巴细胞白血病病程差异大,与分子异质性相关。
  • 靶向药物获批后多数患者仍不可避免复发或持续存在。
  • 全基因组测序可识别亚克隆突变谱和生长动力学。

核心结论

  • 理解遗传、表观遗传和转录组特征对克隆生长动力学和药物反应的影响,是选择和时机治疗的重要步骤。

研究设计与样本

  • 基于过去十年多项大规模DNA测序研究的综述性总结,未报告具体样本量。

主要发现

  • 肿瘤内亚克隆群体展示广泛的体细胞突变谱、多样的治疗反应水平、再增殖模式和生长动力学。

临床怎么用

  • 全基因组测序有助于识别亚克隆群体,可能指导治疗选择和时机。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic lymphocytic leukemia has a highly variable disease course across patients, thought to be driven by the vast inter- and intrapatient molecular heterogeneity described in several large-scale DNA-sequencing studies conducted over the past decade. Although the last 5 years have seen a dramatic shift in the therapeutic landscape for chronic lymphocytic leukemia, including the regulatory approval of several potent targeted agents (ie, idelalisib, ibrutinib, venetoclax), the vast majority of patients still inevitably experience disease recurrence or persistence. Recent genome-wide sequencing approaches have helped to identify subclonal populations within tumors that demonstrate a broad spectrum of somatic mutations, diverse levels of response to therapy, patterns of repopulation, and growth kinetics. Understanding the impact of genetic, epigenetic, and transcriptomic features on clonal growth dynamics and drug response will be an important step toward the selection and timing of therapy.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Gutierrez C, Wu CJ. Clonal dynamics in chronic lymphocytic leukemia. Blood Adv. 2019. PMID: 31770443. doi:10.1182/bloodadvances.2019000367

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。